Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smoked THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects
NCT05037487Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dronabinol and cannabidiol (4 arms), sponsored by University of California, Los Angeles. Primary endpoints: Subjective drug effect ratings of impairment and abuse liability at 6 hours, Pharmacokinetics of THC, CBD and metabolites at 6 hours and 2 more. Started Sep 2022; status: completed.
02
Drugs
dronabinolcannabidiol
Beyond the preview
Go deeper on NCT05037487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037487.